PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30217020-0	2018	A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation.	mhy2256	47-54	tumor protein p53	Homo sapiens	131-134
30217020-1	2018	We previously discovered a novel sirtuin (SIRT) inhibitor, MHY2256, that exerts anticancer activity through p53 acetylation in MCF-7 human breast cancer cells.	mhy2256	59-66	tumor protein p53	Homo sapiens	108-111
27994519-0	2016	Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding.	mhy2256	44-51	MDM2 proto-oncogene	Homo sapiens	111-115
27994519-0	2016	Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding.	mhy2256	44-51	tumor protein p53	Homo sapiens	116-119
27994519-8	2016	MHY2256 showed potent inhibition (IC50, 0.27 mM) against SIRT1 enzyme activity compared with nicotinamide (IC50, >1 mM).	mhy2256	0-7	sirtuin 1	Homo sapiens	57-62
27994519-9	2016	Moreover, expression of SIRT (1, 2, or 3) protein levels was significantly reduced by MHY2256 treatment in both MCF-7 and SKOV-3 cells.	mhy2256	86-93	sirtuin 1	Homo sapiens	24-40
27994519-11	2016	A significant increase in acetylated p53, a target protein of SIRT, was observed in MCF-7 cells after MHY2256 treatment.	mhy2256	102-109	tumor protein p53	Homo sapiens	37-40
27994519-14	2016	These results suggest that a new SIRT inhibitor, MHY2256, has anticancer activity through p53 acetylation in MCF-7 human breast cancer cells.	mhy2256	49-56	tumor protein p53	Homo sapiens	90-93
33073770-2	2020	MHY2256 significantly suppressed the activity of sirtuin 1 and expression levels of sirtuin 1/2 and stimulated acetylation of forkhead box O1, which is a target protein of sirtuin 1.	mhy2256	0-7	sirtuin 1	Homo sapiens	49-58
33073770-2	2020	MHY2256 significantly suppressed the activity of sirtuin 1 and expression levels of sirtuin 1/2 and stimulated acetylation of forkhead box O1, which is a target protein of sirtuin 1.	mhy2256	0-7	sirtuin 1	Homo sapiens	84-95
33073770-2	2020	MHY2256 significantly suppressed the activity of sirtuin 1 and expression levels of sirtuin 1/2 and stimulated acetylation of forkhead box O1, which is a target protein of sirtuin 1.	mhy2256	0-7	forkhead box O1	Homo sapiens	126-141
33073770-2	2020	MHY2256 significantly suppressed the activity of sirtuin 1 and expression levels of sirtuin 1/2 and stimulated acetylation of forkhead box O1, which is a target protein of sirtuin 1.	mhy2256	0-7	sirtuin 1	Homo sapiens	84-93
33073770-3	2020	Treatment with MHY2256 inhibited the growth of the HCT116 (TP53 wild-type), HT-29 (TP53 mutant), and DLD-1 (TP53 mutant) human colorectal cancer cell lines.	mhy2256	15-22	tumor protein p53	Homo sapiens	59-63
33073770-3	2020	Treatment with MHY2256 inhibited the growth of the HCT116 (TP53 wild-type), HT-29 (TP53 mutant), and DLD-1 (TP53 mutant) human colorectal cancer cell lines.	mhy2256	15-22	tumor protein p53	Homo sapiens	83-87
33073770-3	2020	Treatment with MHY2256 inhibited the growth of the HCT116 (TP53 wild-type), HT-29 (TP53 mutant), and DLD-1 (TP53 mutant) human colorectal cancer cell lines.	mhy2256	15-22	tumor protein p53	Homo sapiens	83-87
33073770-4	2020	In addition, MHY2256 induced G0/G1 phase arrest of the cell cycle progression, which was accompanied by the reduction of cyclin D1 and cyclin E and the decrease of cyclin-dependent kinase 2, cyclin-dependent kinase 4, cyclin-dependent kinase 6, phosphorylated retinoblastoma protein, and E2F transcription factor 1.	mhy2256	13-20	cyclin D1	Homo sapiens	121-130
33073770-4	2020	In addition, MHY2256 induced G0/G1 phase arrest of the cell cycle progression, which was accompanied by the reduction of cyclin D1 and cyclin E and the decrease of cyclin-dependent kinase 2, cyclin-dependent kinase 4, cyclin-dependent kinase 6, phosphorylated retinoblastoma protein, and E2F transcription factor 1.	mhy2256	13-20	cyclin dependent kinase 2	Homo sapiens	164-189
33073770-4	2020	In addition, MHY2256 induced G0/G1 phase arrest of the cell cycle progression, which was accompanied by the reduction of cyclin D1 and cyclin E and the decrease of cyclin-dependent kinase 2, cyclin-dependent kinase 4, cyclin-dependent kinase 6, phosphorylated retinoblastoma protein, and E2F transcription factor 1.	mhy2256	13-20	cyclin dependent kinase 4	Homo sapiens	191-216
33073770-4	2020	In addition, MHY2256 induced G0/G1 phase arrest of the cell cycle progression, which was accompanied by the reduction of cyclin D1 and cyclin E and the decrease of cyclin-dependent kinase 2, cyclin-dependent kinase 4, cyclin-dependent kinase 6, phosphorylated retinoblastoma protein, and E2F transcription factor 1.	mhy2256	13-20	cyclin dependent kinase 6	Homo sapiens	218-243
33073770-4	2020	In addition, MHY2256 induced G0/G1 phase arrest of the cell cycle progression, which was accompanied by the reduction of cyclin D1 and cyclin E and the decrease of cyclin-dependent kinase 2, cyclin-dependent kinase 4, cyclin-dependent kinase 6, phosphorylated retinoblastoma protein, and E2F transcription factor 1.	mhy2256	13-20	E2F transcription factor 1	Homo sapiens	288-314
33073770-7	2020	MHY2256-induced apoptosis was involved in the activation of caspase-8, -9, and -3 and was prevented by pretreatment with Z-VAD-FMK, a pan-caspase inhibitor.	mhy2256	0-7	caspase 8	Homo sapiens	60-81